if I have 4 different conditions with 3 replicates what test should I run? I did a lab where I observed 3 different levels of caffeinated dilution and control as my spring water, each condition had 3 replicas?

1) What are you testing in the picture above? 2) How would you interpret this test? 3) What is the basis for this type of test?

Following is the data and notice that it is a terrible idea to culture hMSCs longer than 10 days. You’re strongly Days # cells0 50001 75002 125003 125004 218005 287006 530007 1143008 1653009 19200010 19200011 11680012 8950013 8830014 78300 Part1 You are working for a start-up that is pursuing a clinical trial. The trial involves grafting hMSCs intopatients suffering from interveterbral disc disease using a degradable polymer scaffold. You are going to 3Dprint a porous cylindrical scaffold that is 2 cm in radius and 1 cm in height (matching the dimensions of adegenerated disc). Assume a porosity of 50%. You will fill available volume of the scaffold with hMSCs at adensity of 1 million cells per cm3. Based on the data above, what starting number of cells will you use andhow long will it take you to get enough cells for the trial? Part2The trial is a failure (patients did not report any reduction in back pain). Your team wants to try againusing 85% hMSCs and 15% nucleus pulposus cells .…

You also obtained the MIC for a variety of common antifungals by testing them against a single strain of Aspergillus fumigatis. Six replicates of each were tested.   MIC (ug/mL) Amphotericin B 1 Miconazole 0.06 Ciclopirox 0.01 Nystatin 0.625 New product 0.1   Two-way ANOVA Amp v. New 3.70E-04 Nys v. New 4.16E-05 Mico v. New 0.04 Cic vs. New 1.50E-05 Additionally, Candida aurus is a fungus that is rapidly becoming resistant to multiple antifungals. Because strains now exist that are completely resistant to three or more families of antifungals, there is room in the market for an antifungal that is effective against C. aurus. If the data above is representative for the efficacy against both A. fumigatus, a fungus that is plentiful and sensitive to most antifungals, and C. aurus, determine whether this efficacy data supports room for this product on the existing marketplace. If you think more data is required in order to make a final decision about this…

This is what I was tested on last week. All the information is already in the question. The professor gave me no other information. Is my professor wrong?

You perform a plaque assay with your bacteria and serial dilutions of your bacteriophage, , and then count the plaques. In the 10-5 dilution you have 318 plaques. In the 10-6 dilution, you count 32 plaques, and in the 10-7 dilution, there are 3 plaques. What is the approximate PFU/cell of your sample? 3.2 x 105 318 3.2 x 107 O 3.2 x 106

Since higher concentration colcemid will result in shorter chromosome, you want to      change your protocol and  reduce final concentration of colcemid in your 10 ml blood      culture from 0.1ug/ml to 0.05ug/ml. how many ul colcemid stock solution with      concentration10ug/ml needed to be added in 10ml blood culture?

a sample was found to contain 10.0ug/L of nitrate. a spike of 5 ug/L was added to a replicate unknown, and the spiked sample was found to contain 14.6 ug/L. what is the percent recovery?

Why is an antibody used in this experiment?

What is the purpose of conducting a modified Furter-Meyer Test? What is the principle behind this test? How could you identify the positive result for this test?